Facebook
Twitter
LinkedIn
Forward
Rethinking Outflow in Glaucoma: The Role of Nitric Oxide (Archived CE Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
New additions to the glaucoma treatment arsenal can result in better outcomes for patients with glaucoma and ocular hypertension. Optometrists who treat these patients need to keep abreast of how new these treatments work and determine how best to incorporate them into clinical practice on the basis of evidence from pivotal clinical trials.
The goals of this activity are to help optometrists better understand the influences of nitric oxide on the trabecular meshwork and to integrate new therapy based on safety and efficacy in preventing glaucoma progression.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the downstream signaling effects of nitric oxide in relation to glaucoma
- Discuss the effects of nitric oxide on the trabecular meshwork
- Apply data from clinical trials on nitric oxide–donating agent(s) for lowering intraocular pressure
Faculty
 | Murray Fingeret, OD, FAAO (Chair) Clinical Professor State University of New York College of Optometry New York, New York |
 | Michael Chaglasian, OD, FAAO Chief of Staff Illinois Eye Institute Associate Professor Illinois College of Optometry Chicago, Illinois |
 | Louis R. Pasquale, MD, FARVO Professor of Ophthalmology Icahn School of Medicine at Mount Sinai Site Chair, Department of Ophthalmology The Mount Sinai Hospital and Mount Sinai Queens Deputy Chair, Ophthalmology Research Director, Eye and Vision Research Institute Mount Sinai Health System New York, New York |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Michael Chaglasian, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Contracted Research: Heidelberg Engineering GmbH; and Topcon Medical Systems, Inc.
Murray Fingeret, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Heidelberg Engineer GmbH; Ivantis Inc; and Topcon Medical Systems, Inc.
Louis R. Pasquale, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Bausch & Lomb Incorporated; Eyenovia, Inc; Nicox; and Verily Life Sciences LLC.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 65781-GL (Enduring Distance Learning)
COPE Course Category: Glaucoma
Administrator: 
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This continuing education activity is copyrighted to MedEdicus LLC ©2019. All rights reserved. 188